Hospital CostsPhase 4NCT02233400
A Trial of the Cost Effectiveness of IV Acetaminophen in Bariatric Surgery
A Phase 4 study testing Acetaminophen in people with Hospital Costs and Length of Stay, run by St. Luke's Hospital and Health Network, Pennsylvania at 2 sites in United States.
Trial summary
Bariatric surgery is the only proven and effective long term treatment for morbid obesity. In an attempt to reduce patients' post-operative hospital stay, lower associated health care costs, and improve satisfaction scores, St Luke's University Health Network (SLUHN) recently adopted a fast track bariatric surgery… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hospital Costs, Length of Stay, Postoperative Pain Score
- What is being tested?
- Acetaminophen
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 113 participants
- Where
- 2 sitesUnited States
- Study dates
- Feb 2013to Jul 2014
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age > 18
- attendance at an informational seminar and support group
- clearance for surgery by a registered dietician and certified social worker
- BMI > 35 with at least one co-morbid condition (e.g., hypertension, diabetes mellitus, sleep apnea, hypercholesterolemia) or BMI > 40 without any co-morbid conditions
- negative pregnancy test
- American Society of Anesthesiology score 1-3
Show all 11Show fewer
- ability to understand instructions and comply with all study requirements
- preoperative %excess weight loss (%EWL) of 3-10%
- no contraindication for a LRYGB or LSG based on upper endoscopy findings
- preoperative cardiac consultation for risk stratification
- evaluation by a sleep medicine specialist to identify risk factors for sleep apnea, with treatment as deemed appropriate
Who cannot join
- revisional surgery
- conversion to open procedure
- chronic musculoskeletal pain
- narcotics or NSAIDs use in the 7 days prior to surgery
- history of fibromyalgia
- sensitivity to acetaminophen or liver disease (i.e., elevated LFT or history of hepatitis or liver failure)
Show all 9Show fewer
- use of monoamine oxidase inhibitor in the 7 days prior to surgery
- use of any medication containing acetaminophen
- allergy to morphine or oxycodone
Trial locations and contacts
2 sites in 1 country.
United States2 sites
St Luke's University Hospital
Allentown, Pennsylvania, 18104
St Luke's University Health Network
Bethlehem, Pennsylvania, 18015
About this study
Official title: IV Acetaminophen Results in Lower Hospital Costs and Emergency Room Visits Following Bariatric Surgery: A Double-Blind Prospective Randomized Trial in A Single Accredited Bariatric Center
Bariatric surgery is the only proven and effective long term treatment for morbid obesity. In an attempt to reduce patients' post-operative hospital stay, lower associated health care costs, and improve satisfaction scores, St Luke's University Health Network (SLUHN) recently adopted a fast track bariatric surgery (FTBS) protocol. Findings to date show that FTBS is safe and effective when performed in a Center of Excellence (COE) such as ours. However, post-operative pain control remains a challenging issue, with only intravenous (IV) or PO (by mouth) narcotics appropriate for bariatric surgery patients.
IV acetaminophen, which has been used successfully in Europe, was recently approved by the Federal Drug Administration (FDA) for use in the US. However, no data exist regarding the use of IV acetaminophen in bariatric surgery patients, nor are there any data assessing its cost effectiveness. Therefore, our study will investigate the economic impact of administering IV acetaminophen to bariatric surgery patients, as well as its effect on clinical outcomes such as patients' post-operative length of stay, self-reported pain, readmissions, emergency room (ER) visits and complications.
The study design will be a randomized, double-blind, parallel-group, controlled trial in a single bariatric Center of Excellence (COE) that is part of the St. Luke's University Health Network (SLUHN). Patients will consist of up to 200 morbidly obese adult bariatric surgery candidates > 18 years of age undergoing either laparoscopic Roux-en-Y Gastric Bypass (LRYGB) or laparoscopic Sleeve Gastrectomy (LSG). Group 1 (treatment) will receive IV acetaminophen plus IV narcotics for the first 6 hours post-surgery followed by IV/ PO narcotics for the remaining 18 hours. Group 2 (control) will receive IV normal saline plus IV narcotics for the first 6 hours post-surgery followed by IV/PO narcotics for the remaining 18 hours. Data analysis will include quantile regression, mixed randomized-repeated analysis of covariance (ANCOVA) and selected univariate comparisons, with p < .05 denoting statistical significance for all outcomes.
Read the detailed description
This was a double-blind, prospective, randomized controlled trial conducted at a single accredited bariatric center that is part of a multi-campus university teaching hospital. The Institutional Review Board approved the study.
We hypothesized that administering IV acetaminophen plus IV narcotics/PO narcotics to bariatric patients will produce significant cost savings to our hospital network, as well as result in lower self-reported pain from baseline to 24 hours post-surgery; a decrease in hospital length of stay (LOS) to < 24 hours; and higher overall patient satisfaction compared to patients receiving IV narcotics plus normal saline as placebo.
Based on the smallest clinically meaningful difference in mean pain scores of < 3 for the IV Acetaminophen group versus > 5 for the normal saline group (representing a minimum reduction of 40%), 24 patients are required to achieve 92% power at α = .05.
To ensure an adequate number of complete data points, a decision was made to recruit a total of 100 patients. Inclusion and exclusion criteria are presented in table 1.
Patients were randomly assigned to either treatment or control groups in a 1:1 ratio using permuted block sizes of 8.
To preserve blinding of group assignment among the surgeons, patients, nurses and other team members, randomization numbers generated by the statistician were printed out and placed on the medication infusion bags by the pharmacist.
Group 1 (treatment) received IV acetaminophen (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) 30 minutes before surgery, followed by medication plus IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
Group 2 (control) received IV normal saline (100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) 30 minutes before surgery, followed by saline plus IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
Pain was formally assessed every 2 hours for the first 24 hours post-surgery using a 10-point ordinal scale, with 0 representing no pain and 10 representing the worst pain. Rescue narcotics were given as needed depending on whether self-reported pain is moderate (4-6 on 10-point pain scale) or severe (> 7 on 10-point pain scale).
In the first 6 hours, patients were only offered IV narcotics. After the first 6 hours, patients were offered either IV or PO narcotics as deemed appropriate by the administering nurse based on the clinical condition and ability to tolerate PO intake. For moderate pain, patients received either IV morphine 2 mg IV Q2hrs PRN or PO Oxycodone 5 ml PO Q4hrs PRN. For severe pain, patients received either IV morphine 4 mg IV Q2hrs PRN or PO Oxycodone 10 ml PO Q4hrs PRN.
Total hospital network costs for all relevant services were represented in dollar amounts as a continuous variable. Total costs included both direct and indirect costs. Direct costs were based on postoperative length of stay and the cost associated with acetaminophen and narcotic administration. Indirect costs included the cost of ER visits secondary to postoperative pain and also the performance of any radiographic studies postoperatively to evaluate for abdominal pain as deemed clinically necessary by the attending surgeon.
Hospital length of stay (LOS) was dichotomized as < 24 hours and > 24 hours, given the expected relative infrequency of patients requiring a stay > 24 hours.
Patients' self-reported satisfaction was assessed using a 5-point Likert scale (from strongly disagree to strongly agree) at 10 days to 2 weeks post-surgery (see Figure 1).
Descriptive outcomes are reported as means and standard deviations for normally distributed continuous variables; medians and interquartile ranges for skewed continuous variables; and frequencies and percentages for categorical variables
Primary outcomes included the following variables
- Total hospital network direct costs (including direct cost per adjusted patient day and costs for IV acetaminophen, morphine and narcotics administration):
The original data analysis plan called for quantile regression with the covariates of treatment group (IV acetaminophen plus narcotics versus IV narcotics plus normal saline) and surgery type (LRYGB versus LSG), based on the assumption that the direct cost data would be skewed with unequal variance across the distribution of sample group outcomes.
However, preliminary inspection of the data revealed that basic assumptions of normality of sampling distributions, homogeneity of variance and absence of significantly influential outliers were met. Therefore, we conducted factorial randomized-groups analysis of variance (ANOVA) with the between-group factors of treatment group and surgery type, as well as the treatment group * surgery type interactional effect.
- Mean self-reported pain scores: mixed randomized-repeated measures analysis of covariance (ANCOVA) with the randomized factors of treatment group (IV acetaminophen plus narcotics versus IV narcotics plus normal saline) and surgery type (LRYGB versus LSG); the repeated measures factor of pain scores over time (i.e., 2-hours intervals from 2 to 22 hours); and the first post-operative pain scale assessment as the covariate. Pain scores were measured on a numeric scale, with 0 representing no pain and 10 representing the worst imaginable pain. Prior to data analysis, the assumptions of normality of sampling distributions, homogeneity of variance, presence of significantly influential outliers, linearity between the baseline pain score covariate and subsequent pain scores, and homogeneity of regression for the covariate-outcomes slopes were evaluated. These assumptions were met with the exception of moderate heterogeneity of variance for the IV acetaminophen-LSG group for 10-hour pain scores and largely curvilinear relationships between the covariate and subsequent pain scores. Therefore, the covariate was logarithmically transformed, and a more conservative p-value < .025 was used to assess pain scores over time. In order to obtain a clearer understanding of the repeated measures main effect of pain scores over time, an additional analysis of variance excluding the covariate of baseline pain scores was also conducted.
- Length of stay (< 24 hours versus > 24 hours): Cochran-Mantel-Haenszel test for treatment group with surgery type as the stratification variable.
- Patient satisfaction: a patient satisfaction survey was given to all the patients in our study to fill during their first postoperative visit between Post-Operative Day (POD) #7 and POD# 10. The questionnaires are filled by the patients and collected by our study coordinator for analysis before the patient is examined by the surgeon to avoid any bias in reporting satisfaction scores. Separate Mann Whitney rank sums tests by treatment group and surgery type
- Patient rating of overall pain: pain overall score (0-10) was also collected during the first postoperative visit between POD#7 and POD#10 factorial randomized-groups ANOVA by treatment group, surgery type and treatment group*surgery type interaction
- Being tested
- Acetaminophen
- Keywords
- Acetaminophen, Gastric Bypass, Sleeve Gastrectomy, Pain, Cost
- Medical subject headings
- Patient Satisfaction, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AcetaminophenDrug
Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
| Study group | Role | What they receive |
|---|---|---|
| Treatment | Experimental | Group 1 (treatment) will receive IV acetaminophen (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours. Receives: Drug: Acetaminophen |
| Control | No intervention | Group 2 (control) will receive IV normal saline (100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain Scale
Measured: 24 hours
length of stay
Measured: less than or greater than 24 hours
Direct Hospital Costs
Measured: 6 months
Patient Satisfaction
Measured: 10 days
Secondary outcomes (5)
ER visits
Measured: 30 days
Indirect Hospital Costs
Measured: 24 to 48 hours
Readmissions
Measured: 30 days
Complications
Measured: 30 days
Amount of narcotics used
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2014 (estimated)
- Study startFeb 2013
- Primary completionJan 2014
- Study completionJul 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hospital CostsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 113 participants (actual)
Sponsor and investigators
- Lead sponsor
- St. Luke's Hospital and Health Network, Pennsylvania
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maher El Chaar, MD, St. Luke's Hospital and Health Network, Pennsylvania
- Investigators
- Maher El Chaar, MD, Principal investigator, St Luke's University Hospital and Health Network
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02233400
- Sponsor's protocol ID
- SLHN 2012-102
- Status last verified
- Sep 2014
- First submitted
- 27 Jan 2013
- Last updated
- 8 Sep 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- IV Acetaminophen Results in Lower Hospital Costs and Emergency Room Visits Following Bariatric Surgery: A Double-Blind Prospective Randomized Trial in A Single Accredited Bariatric Center
- ClinicalTrials.gov ID
- NCT02233400
- Acronym / sponsor ID
- SLHN 2012-102
- Keywords
- Acetaminophen, Gastric Bypass, Sleeve Gastrectomy, Pain, Cost
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 113 participants (actual)
- Lead sponsor
- St. Luke's Hospital and Health Network, PennsylvaniaUniversity, hospital or other
- Study start
- Feb 2013
- Primary completion
- Jan 2014 (actual)
- Study completion
- Jul 2014 (actual)
- First posted
- 8 Sep 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Bariatric surgery is the only proven and effective long term treatment for morbid obesity. In an attempt to reduce patients' post-operative hospital stay, lower associated health care costs, and improve satisfaction scores, St Luke's University Health Network (SLUHN) recently adopted a fast track bariatric surgery (FTBS) protocol. Findings to date show that FTBS is safe and effective when performed in a Center of Excellence (COE) such as ours. However, post-operative pain control remains a challenging issue, with only intravenous (IV) or PO (by mouth) narcotics appropriate for bariatric surgery patients.
IV acetaminophen, which has been used successfully in Europe, was recently approved by the Federal Drug Administration (FDA) for use in the US. However, no data exist regarding the use of IV acetaminophen in bariatric surgery patients, nor are there any data assessing its cost effectiveness. Therefore, our study will investigate the economic impact of administering IV acetaminophen to bariatric surgery patients, as well as its effect on clinical outcomes such as patients' post-operative length of stay, self-reported pain, readmissions, emergency room (ER) visits and complications.
The study design will be a randomized, double-blind, parallel-group, controlled trial in a single bariatric Center of Excellence (COE) that is part of the St. Luke's University Health Network (SLUHN). Patients will consist of up to 200 morbidly obese adult bariatric surgery candidates > 18 years of age undergoing either laparoscopic Roux-en-Y Gastric Bypass (LRYGB) or laparoscopic Sleeve Gastrectomy (LSG). Group 1 (treatment) will receive IV acetaminophen plus IV narcotics for the first 6 hours post-surgery followed by IV/ PO narcotics for the remaining 18 hours. Group 2 (control) will receive IV normal saline plus IV narcotics for the first 6 hours post-surgery followed by IV/PO narcotics for the remaining 18 hours. Data analysis will include quantile regression, mixed randomized-repeated analysis of covariance (ANCOVA) and selected univariate comparisons, with p < .05 denoting statistical significance for all outcomes.
Detailed description
This was a double-blind, prospective, randomized controlled trial conducted at a single accredited bariatric center that is part of a multi-campus university teaching hospital. The Institutional Review Board approved the study.
We hypothesized that administering IV acetaminophen plus IV narcotics/PO narcotics to bariatric patients will produce significant cost savings to our hospital network, as well as result in lower self-reported pain from baseline to 24 hours post-surgery; a decrease in hospital length of stay (LOS) to < 24 hours; and higher overall patient satisfaction compared to patients receiving IV narcotics plus normal saline as placebo.
Based on the smallest clinically meaningful difference in mean pain scores of < 3 for the IV Acetaminophen group versus > 5 for the normal saline group (representing a minimum reduction of 40%), 24 patients are required to achieve 92% power at α = .05.
To ensure an adequate number of complete data points, a decision was made to recruit a total of 100 patients. Inclusion and exclusion criteria are presented in table 1.
Patients were randomly assigned to either treatment or control groups in a 1:1 ratio using permuted block sizes of 8.
To preserve blinding of group assignment among the surgeons, patients, nurses and other team members, randomization numbers generated by the statistician were printed out and placed on the medication infusion bags by the pharmacist.
Group 1 (treatment) received IV acetaminophen (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) 30 minutes before surgery, followed by medication plus IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
Group 2 (control) received IV normal saline (100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) 30 minutes before surgery, followed by saline plus IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
Pain was formally assessed every 2 hours for the first 24 hours post-surgery using a 10-point ordinal scale, with 0 representing no pain and 10 representing the worst pain. Rescue narcotics were given as needed depending on whether self-reported pain is moderate (4-6 on 10-point pain scale) or severe (> 7 on 10-point pain scale).
In the first 6 hours, patients were only offered IV narcotics. After the first 6 hours, patients were offered either IV or PO narcotics as deemed appropriate by the administering nurse based on the clinical condition and ability to tolerate PO intake. For moderate pain, patients received either IV morphine 2 mg IV Q2hrs PRN or PO Oxycodone 5 ml PO Q4hrs PRN. For severe pain, patients received either IV morphine 4 mg IV Q2hrs PRN or PO Oxycodone 10 ml PO Q4hrs PRN.
Total hospital network costs for all relevant services were represented in dollar amounts as a continuous variable. Total costs included both direct and indirect costs. Direct costs were based on postoperative length of stay and the cost associated with acetaminophen and narcotic administration. Indirect costs included the cost of ER visits secondary to postoperative pain and also the performance of any radiographic studies postoperatively to evaluate for abdominal pain as deemed clinically necessary by the attending surgeon.
Hospital length of stay (LOS) was dichotomized as < 24 hours and > 24 hours, given the expected relative infrequency of patients requiring a stay > 24 hours.
Patients' self-reported satisfaction was assessed using a 5-point Likert scale (from strongly disagree to strongly agree) at 10 days to 2 weeks post-surgery (see Figure 1).
Descriptive outcomes are reported as means and standard deviations for normally distributed continuous variables; medians and interquartile ranges for skewed continuous variables; and frequencies and percentages for categorical variables
Primary outcomes included the following variables
- Total hospital network direct costs (including direct cost per adjusted patient day and costs for IV acetaminophen, morphine and narcotics administration):
The original data analysis plan called for quantile regression with the covariates of treatment group (IV acetaminophen plus narcotics versus IV narcotics plus normal saline) and surgery type (LRYGB versus LSG), based on the assumption that the direct cost data would be skewed with unequal variance across the distribution of sample group outcomes.
However, preliminary inspection of the data revealed that basic assumptions of normality of sampling distributions, homogeneity of variance and absence of significantly influential outliers were met. Therefore, we conducted factorial randomized-groups analysis of variance (ANOVA) with the between-group factors of treatment group and surgery type, as well as the treatment group * surgery type interactional effect.
- Mean self-reported pain scores: mixed randomized-repeated measures analysis of covariance (ANCOVA) with the randomized factors of treatment group (IV acetaminophen plus narcotics versus IV narcotics plus normal saline) and surgery type (LRYGB versus LSG); the repeated measures factor of pain scores over time (i.e., 2-hours intervals from 2 to 22 hours); and the first post-operative pain scale assessment as the covariate. Pain scores were measured on a numeric scale, with 0 representing no pain and 10 representing the worst imaginable pain. Prior to data analysis, the assumptions of normality of sampling distributions, homogeneity of variance, presence of significantly influential outliers, linearity between the baseline pain score covariate and subsequent pain scores, and homogeneity of regression for the covariate-outcomes slopes were evaluated. These assumptions were met with the exception of moderate heterogeneity of variance for the IV acetaminophen-LSG group for 10-hour pain scores and largely curvilinear relationships between the covariate and subsequent pain scores. Therefore, the covariate was logarithmically transformed, and a more conservative p-value < .025 was used to assess pain scores over time. In order to obtain a clearer understanding of the repeated measures main effect of pain scores over time, an additional analysis of variance excluding the covariate of baseline pain scores was also conducted.
- Length of stay (< 24 hours versus > 24 hours): Cochran-Mantel-Haenszel test for treatment group with surgery type as the stratification variable.
- Patient satisfaction: a patient satisfaction survey was given to all the patients in our study to fill during their first postoperative visit between Post-Operative Day (POD) #7 and POD# 10. The questionnaires are filled by the patients and collected by our study coordinator for analysis before the patient is examined by the surgeon to avoid any bias in reporting satisfaction scores. Separate Mann Whitney rank sums tests by treatment group and surgery type
- Patient rating of overall pain: pain overall score (0-10) was also collected during the first postoperative visit between POD#7 and POD#10 factorial randomized-groups ANOVA by treatment group, surgery type and treatment group*surgery type interaction
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment | Experimental | Drug: AcetaminophenGroup 1 (treatment) will receive IV acetaminophen (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours. |
| Control | No intervention | –Group 2 (control) will receive IV normal saline (100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- age > 18
- attendance at an informational seminar and support group
- clearance for surgery by a registered dietician and certified social worker
- BMI > 35 with at least one co-morbid condition (e.g., hypertension, diabetes mellitus, sleep apnea, hypercholesterolemia) or BMI > 40 without any co-morbid conditions
- negative pregnancy test
Key exclusion criteria (9 listed)
- revisional surgery
- conversion to open procedure
- chronic musculoskeletal pain
- narcotics or NSAIDs use in the 7 days prior to surgery
- history of fibromyalgia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AcetaminophenGroup 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours. | Drug | Treatment |
Primary outcome
Pain Scale
Time frame: 24 hours
length of stay
Time frame: less than or greater than 24 hours
Direct Hospital Costs
Time frame: 6 months
Patient Satisfaction
Time frame: 10 days
5 secondary outcomes
ER visits
Time frame: 30 days
Indirect Hospital Costs
Time frame: 24 to 48 hours
Readmissions
Time frame: 30 days
Complications
Time frame: 30 days
Amount of narcotics used
Time frame: 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2014.
Related trials for Hospital Costs
Not yet recruitingPhase 2
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy
Recruiting
Outpatient Physiotherapy vs. mHealth Exercise and Self-Management for Knee Osteoarthritis (MOKneeTOR)
Knee Osteoarthristis
Recruiting
Lifestyle Intervention in the Memory Clinics of General and Academic Hospitals Trial
Lifestyle Intervention, Lifestyle Risk Reduction
Active, not recruitingObservational study
AKI and Delirium Risk Prediction and Cost Burden Study
Acute Kidney Injury, Delirium
Active, not recruitingObservational study
Machine Learning to Predict Factors Affecting Rehabilitation Length of Stay and Healthcare Costs for Neurological Rehabilitation
Stroke, Acquired Brain Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maher El Chaar, MD principal investigator
St Luke's University Hospital and Health Network
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Acetaminophen in people with Hospital Costs and Length of Stay, run by St. Luke's Hospital and Health Network, Pennsylvania at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain Scale (time frame: 24 hours). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2014.